Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.
Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults
25 Jun 2022
PPIs raise death risk in advanced NSCLC patients on antitumour therapy
Treatment with proton pump inhibitors (PPI) appears to increase the risk of mortality among patients with advanced nonsmall cell lung cancer (NSCLC) undergoing systemic antitumour therapy, reveals a recent study.
PPIs raise death risk in advanced NSCLC patients on antitumour therapy
25 Jun 2022
Maintenance niraparib a boon in advanced ovarian cancer
Use of niraparib in the maintenance setting appears to minimize the risk of progression in advanced ovarian cancer patients, with surgical timing having little to no effect on the drug’s efficacy, as shown in a post hoc analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 study.
Maintenance niraparib a boon in advanced ovarian cancer
24 Jun 2022
Oral dexamethasone trumps prednisolone for acute asthma attacks in kids
Oral dexamethasone proved more effective than oral prednisolone for the management of acute exacerbation of mild-to-moderate asthma in children, a study suggests.
Oral dexamethasone trumps prednisolone for acute asthma attacks in kids
24 Jun 2022
Baricitinib delays, lowers frequency of flares in JIA
In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.